ArticleHippocampus2025
Combined Effects of Intermittent Hypoxia and Amyloid Beta on Hippocampal Activity, Its Cholinergic Modulation, and Memory.
Article in Hippocampus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Instability in sleep architecture and intermittent hypoxia underlie cognitive impairment in patients with obstructive sleep apnea.Sleep & breathing = Schlaf & Atmung · 2026Article
- Amyloid-β acute exposition affects the CA1 hippocampal network activity and its topological organization, evaluated with multielectrode arrays.Frontiers in dementia · 2026Article
- MiR-106a-5p in extracellular vesicles derived from alveolar epithelial cells mediates cognitive dysfunction induced by chronic intermittent hypoxia in mice through MAPK signaling pathway.Journal of neuroinflammation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Obstructive sleep apnea (OSA), characterized by repetitive upper airway obstruction, leads to chronic intermittent hypoxia (cIH) and induces cognitive and neuronal network disruptions similar to those observed in Alzheimer's disease (AD). These pathologies are often presented together in the elderly and share some pathophysiological mechanisms. The presence of amyloid beta (Aβ), observed both in AD and OSA patients, can alter brain function, cholinergic modulation and memory either independently or in addition with cIH. To explore these possibilities, we studied the pathological effects of Aβ, cIH, and their combination on cognition and hippocampal activity, and its modulations by the cholinomimetics carbachol, muscarine, and nicotine, along with evaluations of choline acetyltransferase (ChAT) expression in the septum and the hippocampus. We found that cIH and Aβ similarly affect spatial memory and additively impact aversive memory (sparing recognition memory). Although cIH and Aβ share some pathological effects on hippocampal activity and its modulation by cholinomimetics, when combined, they produce an additive inhibition at the population and single-cell levels more evident in the presence of nicotine. No change in ChAT expression was observed. Remarkably, the departure from normal firing as well as the disruption of carbachol-induced response correlates with the reduction of aversive memory in our experimental groups. In summary, cIH and Aβ share pathological effects, but their combination exacerbates functional pathology, contributing to our understanding of AD/OSA pathophysiology and co-morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.